Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

Early Phase 1

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06305286Phase 1Recruiting

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

Role: collaborator

NCT06126380Phase 2Enrolling By Invitation

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Role: lead

NCT05983770Phase 2Completed

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Role: lead

NCT06972069Early Phase 1Recruiting

Tolerance Through Mixed Chimerism (Sip-Tego)

Role: collaborator

NCT05027906Phase 1Recruiting

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Role: lead

NCT05125068Phase 2Terminated

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Role: lead

NCT05480657Phase 1Withdrawn

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

Role: lead

All 7 trials loaded